VEGFA and neoplasm: Bevacizumab, sorafenib, and sunitinib are the most common VEGF inhibitors used in targeted therapy.266 Bevacizumab is a monoclonal antibody that inhibits angiogenesis in tumors.267 The antitumor effect of bevacizumab has been investigated in preclinical tumor models.